Valneva SE (VALN) Non-Current Deferred Tax Liability (2019 - 2026)
Valneva SE (VALN) posted Non-Current Deferred Tax Liability of $5.2 million for Q1 2026, up 1.05% sequentially from $5.1 million in Q4 2025, and up 19.33% YoY from $4.3 million in Q1 2025.
Valneva SE (VALN) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
Valneva SE has reported Non-Current Deferred Tax Liability for 8 years, with the latest figure at $5.2 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 19.33% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (up 19.33% YoY) and the FY2025 annual result came in at $5.1 million, up 13.93% from the prior year.
- Non-Current Deferred Tax Liability advanced to $5.2 million in Q1 2026 per VALN's latest filing, from $5.1 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $14.0 million in Q4 2023 and troughed at $708051.7 in Q4 2022.
- A 5-year average of $3.8 million and a median of $4.0 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability soared 1870.44% in 2023, then slumped 68.12% in 2024.
- Over 5 years, Non-Current Deferred Tax Liability stood at $708051.7 in 2022, then jumped by 1870.44% to $14.0 million in 2023, then plunged by 68.12% to $4.4 million in 2024, then gained by 15.4% to $5.1 million in 2025, then advanced by 1.05% to $5.2 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $5.2 million, $5.1 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.19 Mn |
| Jun 30, 2026 | 5.19 Mn |
| Mar 31, 2026 | 5.19 Mn |
| Mar 31, 2026 | 5.19 Mn |
| Dec 31, 2025 | 5.13 Mn |
| Dec 31, 2025 | 5.13 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Jun 30, 2025 | 4.57 Mn |
| Jun 30, 2025 | 4.57 Mn |
| Mar 31, 2025 | 4.35 Mn |
| Mar 31, 2025 | 4.35 Mn |
| Dec 31, 2024 | 4.45 Mn |
| Dec 31, 2024 | 4.45 Mn |
| Sep 30, 2024 | 4.16 Mn |
| Sep 30, 2024 | 4.16 Mn |
| Jun 30, 2024 | 4.03 Mn |
| Jun 30, 2024 | 4.03 Mn |
| Mar 31, 2024 | 4.02 Mn |
| Mar 31, 2024 | 4.02 Mn |